Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.

Adalimumab dose de-escalation possible in most IBD patients

10 Feb 2019
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Dose de-escalation of adalimumab to 40 mg every 3 weeks is possible in most of the patients with inflammatory bowel disease (IBD), a recent study has shown.

Researchers conducted a retrospective observational study of 56 IBD patients (median age at diagnosis, 25 years; 44.6 percent male) whose adalimumab doses were de-escalated to 40 mg. De-escalation failure was defined as the need for re-escalation, discontinuation of adalimumab treatment, or biochemical, morphological or clinical disease relapse.

Of the patients, 10 had ulcerative colitis while the remaining 46 had Crohn’s disease. The median time on adalimumab medication before de-escalation was 36 months. At the moment of de-escalation, all of the participants were in clinical remission while most (89.3 percent; n=28) were in biochemical remission.

In more than a third of the cases (37.5 percent; n=21), dose de-escalation was a failure, the median time to which was 8.9 years. In this subgroup of patients, 18 (85.7 percent) underwent dose re-escalation due to insufficient disease control. Seventeen of these patients remained on adalimumab medication at the end of the study duration.

In comparison, two-thirds (62.5 percent; n=35) of the participants successfully underwent dose de-escalation, nine of whom eventually stopped adalimumab medication due to deep remission.

Multivariate Cox analysis showed that the only factor significantly correlated with the risk of failure was having an inactive disease on magnetic resonance imaging and/or endoscopy in the year prior to adalimumab de-escalation (hazard ratio, 0.2; 95 percent CI, 0.1–0.8; p=0.02).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.